Latest news with #Intra-CellularTherapies
Yahoo
17-04-2025
- Business
- Yahoo
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Johnson & Johnson (NYSE: JNJ) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%. That extended its dividend growth streak to an impressive 63 years in a row, keeping it in the elite group of Dividend Kings, companies with 50 or more years of annual dividend increases. That payout boost pushes the company's forward dividend yield up to 3.4%, more than double the S&P 500's dividend yield of 1.4%. Johnson & Johnson's high-yielding payout is as healthy as they come, making it a super safe option for those desiring to collect passive dividend income. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Johnson & Johnson has one of the healthiest financial profiles in the world. The healthcare giant has a pristine AAA bond rating. It's one of only two companies in the world with a top credit rating, which is higher than the U.S. government. The company ended the first quarter of this year with only $13.5 billion of net debt: $38.8 billion of cash against $52.3 billion of debt. While that might sound like a lot, it's a paltry total for a company with a $370 billion market cap. It's also a very manageable amount, considering that Johnson & Johnson produced $3.4 billion in free cash flow during its most recent quarter. That was more than enough cash to cover the company's $3 billion dividend outlay in the period. Last year, the company produced $20 billion in free cash flow. That was a more than $1.6 billion improvement from 2023 despite higher litigation settlement payments, higher taxes, and eight months of cash flow from its former consumer health business, Kenvue, in 2023. That growing free cash flow easily covered the company's full-year dividend cost of $11.8 billion. The healthcare company produces significant free cash flow despite investing heavily in research and development (R&D) to discover and test new innovative medicines and medical technologies. Last year, the company poured $17 billion into R&D, accounting for 19.4% of its sales, which kept it as one of the top R&D investors across all industries. Johnson & Johnson has continued to spend heavily on R&D this year, investing $3.2 billion in the first quarter. It has also deployed significant cash into strategic inorganic growth opportunities. It spent over $14 billion in the first quarter to close its acquisition of Intra-Cellular Therapies. That followed deals last year for Shockwave Medical, $13.1 billion; Ambrx, $1.9 billion; and V-Wave, $600 million. These acquisitions helped fill holes in its pipelines, accelerate innovation, and add new products to its MedTech platform. The company's ability to maintain such a strong balance sheet amid this massive shopping spree showcases its financial might. Johnson & Johnson's hefty investments position it to continue growing its revenue and earnings. The company's long-term target is to grow its operational sales at a 5% to 7% compound annual rate from 2025 through 2030. That sales growth should drive its earnings and free cash flow higher, enabling the company to continue increasing its dividend. All investments carry varying levels of risk. Johnson & Johnson's high-yielding dividend is at the low end of the spectrum. The healthcare giant produces prodigious free cash flow that easily covers its payout. It also has one of the strongest balance sheets in the world. Those features allow the company to make heavy investments in R&D and acquisitions to drive future growth. That growth should enable Johnson & Johnson to continue reigning supreme as one of the top dividend stocks to own for a safe and secure income stream that rises each year. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $526,499!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $687,684!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Matt DiLallo has positions in Johnson & Johnson and Kenvue. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy. This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
Wall Street banks are cashing in on trade war chaos
U.S. stock futures edged down Tuesday morning, with the S&P 500, Nasdaq, and Dow Jones Industrial Average trading just below the break-even line as investors braced for a flurry of corporate earnings. The subdued start followed a tech-driven rally on Monday, a temporary lift amid lingering concerns around tariffs and broader economic uncertainty. Goldman Sachs (GS) kicked off the week's earnings slate with a profit jump, even as CEO David Solomon warned of a 'markedly different' environment in the current quarter. Echoing Solomon's sentiments, in March, hedge funds unloaded global stocks at the fastest pace in over a decade — a sign that institutional investors may be growing more cautious as economic uncertainty deepens. Tuesday's earnings lineup includes Bank of America (BAC), Citigroup (C), Johnson & Johnson (JNJ), and Rent the Runway (RENT) before the bell, offering a pulse check across finance, healthcare, and consumer spending. Bank of America beat expectations in the first quarter, with EPS of $0.90 on $27.37 billion in revenue, lifted by a strong showing in its trading division. Like Goldman Sachs, the bank benefited from market volatility, which juiced results even as the broader economic outlook remains uncertain. Looking to Bank of America's consumer banking division, revenue rose 3% to $10.5 billion, with combined credit and debit card spend hitting $228 billion — up 4% from a year ago. The bank added about 250,000 new consumer checking accounts, marking its 25th straight quarter of growth, and saw 4 billion digital logins, with 65% of sales now digitally enabled. Still, CEO Brian Moynihan struck a cautious tone, noting that 'we potentially face a changing economy in the future.' Citigroup posted first-quarter 2025 net income of $4.1 billion, or $1.96 per share, on $21.6 billion in revenue — a 3% increase from a year ago. Growth was broad-based across all five core businesses, with standout performances in the Markets and Wealth divisions. U.S. personal banking revenue rose 2% to $5.2 billion, powered by gains in Branded Cards and Retail Banking, though partially offset by a drop in retail services. Net interest income climbed 6%, fueled by loan growth in branded cards and wider deposit spreads in its retail banking. Johnson & Johnson beat Wall Street expectations in the first quarter, reporting adjusted earnings per share of $2.77 on revenue of $21.89 billion. Sales of cancer drug Darzalex jumped 20% year-over-year to $3.24 billion, helping drive 4.2% growth in the company's Innovative Medicine segment. The healthcare giant raised its full-year revenue guidance to between $91.6 billion and $92.4 billion, reflecting the impact of its Intra-Cellular Therapies acquisition and the addition of Caplyta, a treatment for bipolar depression. However, adjusted EPS guidance held steady at $10.50 to $10.70 as the company factors in tariffs, deal-related costs, and currency headwinds. J&J also moved to reverse $7 billion previously set aside for talc-related legal settlements, after courts rejected its bankruptcy-based strategy for resolving lawsuits over its discontinued baby powder. The company maintains the claims are without merit and says it will defend them in state courts. During a television appearance on Monday, former Treasury Secretary Janet Yellen warned that Trump's economic strategy is eroding global trust in U.S. financial assets, with volatility in Treasury yields reflecting broad investor unease. Treasury yields continued to climb on Tuesday, with the 10-year yield reaching 4.43%, as investors reacted to ongoing trade tensions and concerns over inflation. The bond market's volatility has raised questions about the long-term stability of U.S. financial assets. Both the Dow and the S&P 500 added about 0.8% on Monday, while the Nasdaq climbed about 0.6%. All three indexes briefly slipped into the red before rebounding, buoyed by tech stocks after the Trump administration issued a surprise tariff exemption. Apple (AAPL) stock gained more than 2% on Monday, while Palantir Technologies (PLTR) surged almost 5% following news that NATO had finalized its purchase of the company's AI-powered Maven Smart System. Auto stocks also rallied Monday after President Donald Trump suggested his administration may offer tariff relief for automakers moving parts production. General Motors (GM) and Ford (F) each rose more than 3%, though no specifics were provided. For the latest news, Facebook, Twitter and Instagram.
Yahoo
15-04-2025
- Business
- Yahoo
Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year over year and beating the consensus of $21.58 billion. Operational growth was 4.2%, and adjusted operational growth was 3.3%. Innovative Medicine sales increased 2.3% or 4.2 operationally to $13.90 billion. Also Read: Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, Spravato (esketamine) Neuroscience, and Xarelto in cardiovascular. Growth was partially offset by an approximate (810) basis points impact from Stelara (ustekinumab) in immunology. Cancer sales increased to $5.68 billion, up 17.9% (+20.4 operational). Immunology sales fell to $3.71 billion, down 12.7% (down 10.9% operational). Stelara sales fell 33.7% to $1.63 billion. Darzalex sales rose 20.3% to $3.24 billion. The company's cancer cell therapy, Carvykti, generated sales of $369 million. MedTech sales increased 2.5% to 8.02 billion, driven primarily by Abiomed in cardiovascular and wound closure products in general surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics. Dividend: Johnson & Johnson also announced an increase in its quarterly dividend from $1.24 to $1.30 per share. The 4.8% increased dividend is payable on June 10, with a record date of May 27. Guidance: Johnson & Johnson expects 2025 sales of $91 billion-$91.8 billion versus prior guidance of $90.9 billion–$91.7 billion and consensus of $90.62 billion The Medtech giant expects 2025 adjusted operational EPS of $10.50-$10.70, compared to prior guidance of $10.75–$10.95. It maintained the adjusted EPS outlook of $10.50-$10.70 versus the consensus of $10.50. Adjusted operational EPS excluded the impact of translational currency, which means JNJ anticipates a hit to the bottomline from the impact currency. The company anticipates second-half operational sales growth higher than the first half of 2025. Johnson & Johnson said the increase in full-year 2025 operational sales guidance reflects the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition. Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, the company maintains a full-year 2025 adjusted reported EPS outlook of 6.2% growth at the mid-point. In March, Johnson & Johnson announced its plans to invest more than $55 billion in the U.S. over the next four years. Price Action: JNJ stock is down 0.88% at $153.01 during the premarket session at the last check Tuesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? JOHNSON & JOHNSON (JNJ): Free Stock Analysis Report This article Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Wall Street Journal
15-04-2025
- Business
- Wall Street Journal
J&J Increases Outlook After Beating 1Q Expectations
Johnson & Johnson raised its full-year outlook as it logged better-than-expected profit and revenue in the first quarter. The healthcare-products company on Tuesday said its higher outlook reflects its completed acquisition of mental-illness drug developer Intra-Cellular Therapies. The roughly $15 billion deal in part added Caplyta, a pill that treats bipolar depression and schizophrenia, to J&J's portfolio.
Globe and Mail
14-04-2025
- Business
- Globe and Mail
Johnson & Johnson (JNJ) Is About to Report Its Q1 Earnings Tomorrow. Here Is What to Expect
Healthcare giant Johnson & Johnson (JNJ) is gearing up to release its first-quarter 2025 financials on April 15. JNJ stock has gained over 5% year-to-date, mainly due to solid financials, a sales boost from its recent Intra-Cellular Therapies acquisition, and steady investor returns through consistent dividend payouts. Wall Street analysts expect the company to report earnings of $2.58 per share, representing a 4.8% decrease year-over-year. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Meanwhile, revenues are expected to increase by about 1% from the year-ago quarter to $21.56 billion, according to data from the TipRanks Forecast page. Analysts' Views Ahead of JNJ's Q1 Earnings Ahead of Johnson & Johnson's Q1 earnings, Bank of America Securities analyst Tim Anderson maintained his Hold rating on the stock and decreased the price target from $171 to $159 per share, citing concerns over new tariffs. For Q1, the firm retained its revenue forecast but expects earnings to decrease by 2% due to expected pressure on profit margins and higher costs. Looking ahead to 2025, BofA expects modest revenue growth from new products and recent acquisitions. However, he believes earnings may dip slightly due to currency headwinds and acquisition-related dilution. Meanwhile, Goldman Sachs analyst Asad Haider upgraded JNJ from Neutral to Buy and raised the price target to $172 from $157. He believes worries about the loss of patent protection for drugs like Stelara are overdone. According to him, JNJ's Innovative Medicine unit, which brings in most of the company's profits, should continue to perform well. Options Traders Anticipate a Minor Move Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting a 4.04% move in either direction. Is Johnson & Johnson a Good Stock to Buy? Turning to Wall Street, Johnson & Johnson stock has a Moderate Buy consensus rating based on seven Buys and eight Holds assigned in the last three months. At $169.00, the average JNJ price target implies 11.38% upside potential. See more JNJ analyst ratings Disclosure Disclaimer & Disclosure Report an Issue
